OnBioVC

SEA Medical Systems, Inc.: Series B $3M

arubenstein — Tue, 24 Apr 2012 07:00:58 +0000

SEA Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

AirXpanders, Inc.: Series D $10.3M

arubenstein — Tue, 24 Apr 2012 07:00:52 +0000

AirXpanders (Palo Alto, CA) a clinical-stage biotechnology company focused on implantable breast tissue expanders for breast cancer masectomy patients, closed a $10M Series D financing. Participants include Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Western Technology Innovation.

MC10, Inc.: Series B $2M

arubenstein — Tue, 24 Apr 2012 07:00:47 +0000

MC10 (Cambridge, MA) a development-stage medical device company focused on flexible, portable electronic medical devices for diagnosing, monitoring body functions and performance via parameters such as the heart (ECG), brain (EEG), muscle (EMG), body temp and hydration, closed a $2M Series B financing, bringing the total round to $17.1M. Participants include Aberdare Ventures.

CN Creative, Ltd.: Series A $3.1M

arubenstein — Tue, 24 Apr 2012 07:00:26 +0000

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $1M Series A financing. Participants include Advent Life Sciences.

ImmuneXcite, Inc.: Series A $2.4M

arubenstein — Tue, 24 Apr 2012 07:00:14 +0000

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Pulse Therapeutics, Inc.: Series B $3.1M

arubenstein — Mon, 23 Apr 2012 04:26:12 +0000

Pulse Therapeutics (St. Louis, MO) a development-stage medical device company focused on vascular drug delivery device for blood clots in stroke patients, closed a $3.1M Series B financing. Participants include BioGenerator.

3-V Biosciences, Inc.: Series C $20M

arubenstein — Mon, 23 Apr 2012 04:23:30 +0000

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

CytoPherx, Inc.: Series C $34M

arubenstein — Mon, 23 Apr 2012 04:19:45 +0000

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

MedGenesis Therapeutix, Inc.: Series C $5M

arubenstein — Mon, 23 Apr 2012 04:15:38 +0000

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

Natura, Inc.: Series D $20M

arubenstein — Mon, 23 Apr 2012 04:13:00 +0000

Natura (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

Akebia Therapeutics, Inc.: Series B $4.1M

arubenstein — Thu, 19 Apr 2012 06:11:35 +0000

Akebia Therapeutics (Cincinnati, OH) a preclinical-stage small molecule company focused on anemia, vascular disorders and angiogenesis, closed a $4.1M Series B financing. Participants include Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.

1Q12 White Paper | A is for Innovation And…

arubenstein — Wed, 14 Mar 2012 04:34:42 +0000

A heated debate is raging regarding who exactly were the recipients of the fourth quarter spike in venture dollars – many believe that innovation has recently suffered from a lack of funding while reconstituted products and late-stage assets have benefited from the lions share of risk capital. We are pleased to present our 4Q11 Series A analysis detailing who are the companies that announced closing of their first institutional financing throughout the final twelve weeks of 2011 and details of their sector participation, product type, and development-stages.

Download the White Paper - A is for Innovation And … [HERE]

Promedior, Inc.: Series D $21.5M

arubenstein — Tue, 13 Mar 2012 00:07:47 +0000

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.